Trials / Terminated
TerminatedNCT04348448
Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia
Observational Study on the Use of Canakinumab Administered Subcutaneously in the Treatment of Patients With COVID-19 Pneumonia
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (actual)
- Sponsor
- AUSL Romagna Rimini · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
The study is configured as a retrospective and prospective observational study. The study will be multi-center and will involve all COVID-19 pneumonia patients treated with canakinumab administered subcutaneously.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Canakinumab 150 MG/ML [Ilaris] | COVID-19 |
Timeline
- Start date
- 2020-02-01
- Primary completion
- 2020-05-01
- Completion
- 2020-09-01
- First posted
- 2020-04-16
- Last updated
- 2023-07-21
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT04348448. Inclusion in this directory is not an endorsement.